---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-092689"
form_type: "8-K/A"
ticker: "APM"
cik: "0001734005"
company_name: "Aptorum Group Ltd"
filed_at: "2026-08-21T21:17:44+00:00"
generated_at: "2026-08-21T21:20:09.023534+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Niki BioSolutions closes DiamiR merger; acquired firm posts FY2026 net loss and going-concern doubt

## Summary
- Merger closed July 20, 2026; DiamiR Biosciences became a wholly-owned subsidiary of Niki BioSolutions (formerly Aptorum Group).
- DiamiR FY2026 net loss of $659,936 vs $743,235 in FY2025; revenue grew to $190,355 from $631,729.
- Auditor cites significant working capital deficiency and needs to raise funds; going-concern doubt raised.
- As of May 31, 2026, DiamiR had cash of $112,690, current assets $345,250 and current liabilities $2,191,803.
- DiamiR's outstanding convertible notes are expected to convert to Niki common shares under the merger agreement.

## SEC filing metadata
- accession: 0001213900-26-092689
- form_type: 8-K/A
- ticker: APM
- cik: 0001734005
- company_name: Aptorum Group Ltd
- filed_at: 2026-08-21T21:17:44+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1734005/000121390026092689/0001213900-26-092689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1734005/000121390026092689/ea0301803-8ka1_nikibio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-092689
- JSON: https://secwatch.observer/filing/0001213900-26-092689.json
- Plain text: https://secwatch.observer/filing/0001213900-26-092689.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.